TargetBeta
PCSK9
proprotein convertase subtilisin/kexin type 9 · also NARC-1, FH3, HCHOLA3 · Proprotein convertase subtilisin/kexin family
12 programs in company-led studies act on PCSK9, from 11 companies: 6 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (11 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| inclisiranrule | Novartis | inhibitor | phase 4 | 3715 running | – | the studies' text |
| evolocumabrule | Amgen | – | phase 4 | 452 running | – | NCIt |
| alirocumabrule | Sanofi | – | phase 4 | 481 running | – | NCIt |
| lerodalcibeprule | LIB Therapeutics | inhibitor | phase 3 | 147 running | – | ChEMBL |
| QLC7401rule | Qilu Pharmaceutical | lowers it | phase 3 | 55 running | – | the studies' text |
| SYH2053rule | CSPC Pharmaceutical Group | lowers it | phase 3 | 54 running | – | the studies' text |
| tafolecimabrule | Innovent Biologics | – | phase 3 | 80 running | – | NCIt |
| recaticimabrule | Jiangsu HengRui Medicine | – | phase 3 | 70 running | – | the studies' text |
| SAL003rule | Shenzhen Salubris Pharmaceuticals | – | phase 3 | 30 running | – | the studies' text |
| VERVE-102 | Eli Lilly | – | phase 2 | 22 running | – | a judged reading |
| DNV001rule | Hangzhou Dinovate Biotech | – | phase 2 | 11 running | – | the studies' text |
| RBD7022rule | Qilu Pharmaceutical | lowers it | phase 1 | 21 running | – | the studies' text |
Conditions their studies are in
- Hypercholesterolemia, 10 programs
- Hyperlipoproteinemia Type II, 8 programs
- Homozygous Familial Hypercholesterolemia, 5 programs
- Hyperlipidemias, 5 programs
- Atherosclerosis, 3 programs
- Coronary Artery Disease, 2 programs
- Acute Coronary Syndrome, 1 program
- Cardiovascular Diseases, 1 program
- Dyslipidemias, 1 program
- Myocardial Infarction, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 27, 2026inclisiran · Novartis · phase 4 · NCT06501443
- Dec 29, 2026alirocumab · Sanofi · phase 4 · NCT07477704
- May 29, 2027evolocumab · Amgen · phase 4 · NCT05284747
- Jun 30, 2027DNV001 · Hangzhou Dinovate Biotech · phase 2 · NCT07391722
- Jul 15, 2027SYH2053 · CSPC Pharmaceutical Group · phase 3 · NCT07938034
- Oct 7, 2027QLC7401 · Qilu Pharmaceutical · phase 3 · NCT07444086
- Jul 31, 2028lerodalcibep · LIB Therapeutics · phase 3 · NCT07102511
- Aug 2028VERVE-102 · Eli Lilly · phase 2 · NCT07839936
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.